Fig. 3: Loss of FGFR1 affects cell cycle progression and downregulates the expression of PRC2 core member EZH2. | Leukemia

Fig. 3: Loss of FGFR1 affects cell cycle progression and downregulates the expression of PRC2 core member EZH2.

From: Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma

Fig. 3

(A) Venn Diagram showing the differentially expressed gene in shFGFR1 vs. Vec ctrl analysis (p < 0.05, FC > 2) (B) Enrichment of the DEG obtained in panel A using Enrichr (C) Heatmap to show expression of MCL proliferation signature genes (PSG) in FGFR1 VC vs. knockdown cells of MCL cell lines Z-138 and Granta-519. (D) Cell cycle analysis determined the percentage of the G1 population in VC vs. shFGFR1 cells of Z-138 and Granta-519. (E) Cell cycle analysis determined the percentage of the G1 population in control vs. erdafitinib treated (16 h) cells of Z-138 and Granta-519. 2-way ANOVA (a = 0.05). (F) The hockey plot for the TF co-expressed with DEG was determined by ARCHS analysis. (G) Western blots show EZH2 expression in Z-138, Granta-519, Jeko-1R, and SP-49R control vs. shFGFR1 cells; EZH2 expression in Z138 was probed on the same blot from Fig. S2H. (H) Western blots show EZH2 expression in Z-138, Granta-519, Mino, and Jeko-1R cells upon erdafitinib treatment. (I) Co-immunoprecipitation of EZH2 and KDM2B (PRC1.1), SUZ12 (PRC2) or PCGF4 (PRC1) followed by western blot in Jeko-1R and Z-138 cells. 2% input was loaded with IP with appropriate IgG isotype control, followed by an IP-EZH2 sample.

Back to article page